Pathstone Family Office’s iShares Biotechnology ETF IBB Stock Holding History

Pathstone Family Office’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.82M	Buy	14,845 +9,557	+181%	+$1.22M	0.01%	488
2023 Q2	$671K	Buy	+5,288	New	+$687K	0.01%	624
2022 Q4	–	Sell	-3,371	Closed	-$394K	–	1353
2022 Q3	$394K	Buy	+3,371	New	+$419K	0.01%	785
2021 Q1	–	Sell	-312	Closed	-$47K	–	969
2020 Q4	$47K	Buy	+312	New	+$44.6K	﹤0.01%	525
2020 Q3	–	Sell	-290	Closed	-$40K	–	892
2020 Q2	$40K	Hold	290	–	–	﹤0.01%	342
2020 Q1	$31K	Hold	290	–	–	﹤0.01%	366
2019 Q4	$34.9K	Buy	+290	New	+$32.4K	﹤0.01%	340
2015 Q4	–	Sell	-45	Closed	-$5K	–	128
2015 Q3	$5K	Buy	+45	New	+$5.4K	0.01%	124
2013 Q4	–	Sell	-225	Closed	-$16K	–	265
2013 Q3	$16K	Buy	+225	New	+$14.7K	0.07%	144

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Pathstone Family Office's IBB Position: Q3 2023 in Review

Pathstone Family Office increased its iShares Biotechnology ETF (IBB) stake by 181% in Q3 2023, buying an estimated $1.22M and bringing the position to 14,845 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #488.

Pathstone Family Office first reported a position in IBB in Q3 2013 and has held it in 9 quarters since. 833 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Pathstone Family Office held 14,845 shares of iShares Biotechnology ETF worth $1.82M as of Q3 2023.
Pathstone Family Office bought 9,557 iShares Biotechnology ETF shares in Q3 2023, an estimated $1.22M.
iShares Biotechnology ETF made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #488 holding.
Pathstone Family Office first reported a position in iShares Biotechnology ETF in Q3 2013 and has held it in 9 quarters since.
833 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.